Xilio Therapeutics ( (XLO) ) has shared an announcement.
Xilio Therapeutics announced significant progress in its pipeline and financial updates for Q3 2024, highlighting initial Phase 1C data for its cancer drug vilastobart in combination with atezolizumab. The company plans to release Phase 2 results by year-end, alongside data for its IL-12 therapy, XTX301. Financially, Xilio’s cash position improved to $61.3 million, projecting sufficient funds through mid-2025, as it continues to advance its innovative tumor-activated immuno-oncology therapies.
See more data about XLO stock on TipRanks’ Stock Analysis page.
